For Investors

We screen hundreds.

You see one.

Flusso runs institutional fundraising for exceptional companies from seed to late stage, with life sciences as its deepest specialty. Every mandate is vetted and prepared before it reaches a fund. Most of what approaches us goes nowhere. What reaches you is the fraction aligned to how you underwrite risk, sector, stage, check size, and fit.

The Inbound Problem

Deal flow was never the problem. Signal is.

Screening is the most expensive thing a fund does that never shows up as a line item. Analyst hours on decks that die at the first data-room question. Partner meetings that exist to establish basics a one-pager should have carried. Numbers that fall apart on first contact, after three people have already touched them.

And screening cuts both ways. The deals worth the time arrive looking identical to the ones that aren't, same templates, same confident numbers. The good deal sits unread while the dead one eats a week. That miss never appears in any report. It appears in someone else's portfolio.

Every fund pays for screening. Most just pay in misses.

Track Record

We've sat where you sit.

Both sides of the table, three continents, one bar for what moves.

Krisztina Németh

Founder and Managing Director of Flusso. Trained in medicine. Leads every fundraising mandate.

Alan Mason

Four decades on Wall Street, from Salomon Brothers. $1B+ personally raised.

Andreas Mueller

25 years in US tech, early at Yelp, LinkedIn, and Skype. Active VC at K2X Capital and venture builder.

The Bar

Most companies never make it to you.

Before anything moves toward an investor, it clears the same review:

01
Nothing moves on trust

Claims, the development path, and financing logic are checked against source, not only the founder's deck.

02
The cap table is clean

Ownership, prior terms, and any structure an IC would flag, checked before distribution.

03
The story survives

We pressure-test the case against the objections your committee will raise, before you raise them.

04
The round has a plan

Raise size, use of funds, and timeline that map to the next value step. A raise with a plan behind it, not a random number.

05
The founder holds up

Responsive, prepared, and realistic on terms. If they cannot run our process, they will not survive yours.

06
The standard never slips

Questions answered same day, data-room gaps closed before you find them, a process that doesn't stall.

After The Send

Four things that are true of every send.

The reason it's on your desk.

Nothing goes out broadside. Every send is matched to your mandate: stage, sector or therapeutic fit, check size, and how you underwrite risk. If we cannot say why it fits your fund, it does not reach your fund.

We know the company, not just the deck.

By the time a deal reaches you, we have been inside it for weeks: the science or product, the development path, the financing logic. Your diligence questions have answers on day one, not in week three.

A pass costs you nothing.

Decline in one line, with or without a reason. No chase sequence, no “just circling back,” no pressure to stay warm for our sake. A no ends cleanly, and your relationship with us does not depend on taking every meeting.

Your feedback compounds.

What you pass on, what you ask about, what almost worked. It all feeds the mandate profile, so each send fits tighter than the last. The next deal you see from us will be better.

The Relationship

You hear from us for a reason.

Tell us your mandate once. From then on, you hear from us when something clears the bar and fits, with the reasoning attached. When nothing fits, you hear nothing. Silence means we're screening, not that we forgot you.

There's no fee, no commitment, and no deal you're obligated to look at. You're not subscribing to anything. You're telling us what would have to be true for a deal to be worth your time, and we only show up when it is.

Everything that reaches you earned it.

Where We Operate

Deepest in life sciences. Open to the exceptional.

Sector
Agnostic
Stage
Seed+
Raise Size
$5M +
Geography
US-based
2B+
Collectively transacted
90+
Years combined experience
10k+
Investor relationships
900+
Ventures supported
Deal Flow

Tell us what you're investing in.

Register your mandate →